SEC Form 4 · accession 0000899243-17-023128
Deciphera Pharmaceuticals, Inc. · DCPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Patrick Kelly
Officer — Chief Financial Officer
Period of report
Oct 2, 2017
Accepted (ET)
Oct 2, 2017 · 4:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001654151
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $1.89 | Oct 2, 2017 | M | 30,621 | D | — | Dec 17, 2025 | Common Stock | 173,008 | 0 | D |
| Stock Option (Right to Buy)F3,F1,F2 | $1.89 | Oct 2, 2017 | M | 173,008 | A | — | Dec 17, 2025 | Common Stock | 173,008 | 173,008 | D |
| Stock Option (Right to Buy)F1,F4 | $1.89 | Oct 2, 2017 | M | 6,805 | D | — | Dec 17, 2025 | Common Stock | 38,448 | 0 | D |
| Stock Option (Right to Buy)F3,F1,F4 | $1.89 | Oct 2, 2017 | M | 38,448 | A | — | Dec 17, 2025 | Common Stock | 38,448 | 38,448 | D |
| Stock Option (Right to Buy)F1,F5 | $3.95 | Oct 2, 2017 | M | 1,000 | D | — | Sep 26, 2026 | Common Stock | 5,650 | 0 | D |
| Stock Option (Right to Buy)F3,F1,F5 | $3.95 | Oct 2, 2017 | M | 5,650 | A | — | Sep 26, 2026 | Common Stock | 5,650 | 5,650 | D |
| Stock Option (Right to Buy)F1,F6 | $6.13 | Oct 2, 2017 | M | 18,269 | D | — | Jun 3, 2027 | Common Stock | 103,219 | 0 | D |
| Stock Option (Right to Buy)F3,F1,F6 | $6.13 | Oct 2, 2017 | M | 103,219 | A | — | Jun 3, 2027 | Common Stock | 103,219 | 103,219 | D |
Explanation of responses
- F1Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b).
- F2This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal quarterly installments at the end of each quarter following the vesting commencement date of February 23, 2015, subject to continued service through such dates.
- F3Represents the total number of options to purchase common stock of the Issuer received upon the exchange of options to purchase common stock of Deciphera Pharmaceuticals, Inc. for options to purchase common stock of the Issuer pursuant to the Merger Agreement.
- F4This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of September 30, 2015, subject to continued service through such dates.
- F5This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of July 1, 2016, subject to continued service through such dates.
- F6This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of May 26, 2017, subject to continued service through